



# Project Friendly 2008

1<sup>st</sup> International Young Project Managers Meeting in Brno, Czech Republic

Jakub Schurek

Project Management in Science

# PROJECTS by Jakub Schurek / OUTLINE



- ü background of myself
- ü 3 main points of project making
- ü project benchmarking



P | 2 | B | PROJECTS | TO | BUSINESS |



## PrimeCell a.s. flagship in biotech

„PrimeCell  
Business developer  
and Investment banker in biotech.“

---



PrimeCell specialized in the development and production of medical products in the field of regenerative medicine.



PrimeCell collaborates with a unique Czech scientific base and supports promising scientists and medical doctors.



PrimeCell is focused on portfolio of hi-tech joint-ventures and biomed projects.

[www.primecell.cz](http://www.primecell.cz)



# PROJECTS (by Jakub Schurek)



## ü Project types

Depending on maturity of company

**Strategy, programme**

## ü Project phases

Depending on goals (no default)

**Planning vs. execution**


## ü Project go-no go decision

Budget, scale (0.5; 5; 50 plus MEur)

**Projects**


(the forth aspect / risks)

# STRATEGY *(target)*



# PROJECTS



- ü Turnover (**\$**)
  - ü Demands – people (**€**)
  - ü Demands – time (**1**)
  - ü Profit (**%**)
  - ü Scale (**V**)
  - ü Increase (**ä**)
- semiquantitative
- 
- 
- ü Cover (**P%**)
  - ü Time per one round (**'**)
- qualitative

# PROGRAMME



<i>Process</i>					\$	€	1	%	V	ä	,	P %	Rating
Description													
XZ													
XZ													
XZ													
	XZ												
XY													
	XZ												
XZ													
XZ													
Legal aspects													
Know/how													
Corporate governance													

Maturity of cooperation:

Signed agreement

In touch/preparation

Initial contact

Waiting

# PROJECTS



<i>Process</i>					\$	€	1	%	V	ä	,	P %	Rating
Description													
Product A													
	Product B												
	Innovation												
		Product C											
Legal aspects													
Know/how													
Corporate governance													

Maturity of products:

Ready to sell products

Clinical trials

R&D

Idea



ü Risks have value, which shows the need for their management. (mng. should be with respect to the scale)

**People**